CD8A and melanoma: Conversely, in ICB-resistant cases, such as Patient 13, melanoma cells lacked MHC class I expression and melanocytic markers and CD8+ T cells failed to express activation or checkpoint markers (e.g., PD1, LAG3, TIM3), suggesting a dysfunctional immune microenvironment.